Working… Menu

Hemoadsorption With CytoSorb® in Post-Cardiac Arrest Syndrome (CATCH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03523039
Recruitment Status : Recruiting
First Posted : May 14, 2018
Last Update Posted : January 27, 2021
Information provided by (Responsible Party):
Antoine Schneider, Centre Hospitalier Universitaire Vaudois

Brief Summary:
This prospective single-centre randomized control trial aims at evaluating the safety and efficacy of hemoadsorption with CytoSorb® in 40 patients with Post-Cardiac Arrest Syndrome admitted to the ICU.

Condition or disease Intervention/treatment Phase
Cardiac Arrest Device: CytoSorb® Hemoadsorption Not Applicable

Detailed Description:

Patients presenting Post-Cardiac Arrest Syndrome (PCAS) in the 24 hours following their admission in Intensive Care Unit will be randomly assigned either to a control group (standard of care) either to a "Hemoadsorption" group. In the latter, the patient will be connected in the 6 hours following randomization to an extracorporeal circuit, in which a Cytosorb ® cartridge will be placed. The circuit will be set up in hemoperfusion mode. The therapy will take place for a minimum of 12 hours and a maximum of 24 hours. Anticoagulation will be achieved using a regional heparin-protamin regimen.

Blood samples will be collected at randomization, T1 (6 hours post-randomization), T2 (12 hours after randomization), T3 (24 hours after randomization), T4 (48 hours after randomization) and T5 (48 hours after randomization), to assess change in inflammatory cytokine levels.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Hemoadsorption With CytoSorb® in Post-Cardiac Arrest Syndrome: a Pilot Study (The CATCH Trial: Post Cardiac Arrest Therapy With Cytosorb Hemoadsorption)
Actual Study Start Date : February 18, 2019
Estimated Primary Completion Date : November 2021
Estimated Study Completion Date : March 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cardiac Arrest

Arm Intervention/treatment
Experimental: Hemoadsorption
Hemoadsorption is performed using a CytoSorb® cartridge.
Device: CytoSorb® Hemoadsorption
The therapy is initiated within 6 hours from randomization and maintained for a minimum of 12 consecutive hours to a maximum of 24 consecutive hours.

No Intervention: Control
Post-cardiac arrest management will be conducted as per institutional protocols.

Primary Outcome Measures :
  1. Change in cytokine levels [ Time Frame: From baseline (randomization) to 72 hours after randomization ]
    Plasma levels reduction of the following inflammatory mediators: IL-1β,IL-1Ra, IL-6, IL-8, IL-10 and TNF-α.

  2. Incidence of Treatment-Emergent Adverse Events [ Time Frame: From beginning of hemoadsorption to 24 hours after the end of hemoadsorption, incidence of adverse events such as haemorrhagic complications, catheter-insertion related complications and anaphylactoid reactions ]
    Rate of intervention-related complications

Secondary Outcome Measures :
  1. Vasopressor requirements [ Time Frame: From baseline (randomization) to 72 hours after randomization ]
    Including the number of patients with a 50% decrease in the baseline vasopressor dose after 6, 12, 24, 36 and 48 hours, and the % of patients requiring a vasopressor dose increase within 24 hours of baseline

  2. In-hospital mortality [ Time Frame: Day 14, 28 and 90 after randomization ]
    All-cause mortality

  3. Shock reversal [ Time Frame: Within 24 hours from randomization ]
    Percentage of patients with shock reversal shock reversal being defined in the present study as a norepinephrine dose <0.1μg/kg/min to maintain MAP >60-70 mmHg and a serum lactate level ≤2 mmol/L

  4. Sequential Organ Failure Assessment Score (SOFA) [ Time Frame: Day 1 to 7 after randomization ]
    Total Daily SOFA Score. The score ranges from 0 (best outcome) to 24 (worst outcome).

  5. CRP and Procalcitonin Levels [ Time Frame: Day 1, 2, 3 after randomization ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Adult (≥18 years old) patients admitted to the ICU after CA, at risk of PACS as defined by the presence of at least one of the following characteristics (at any time within 24hrs of CA):

  • Need for a vasoconstrictor (norepinephrine dose > 0.2 µg/kg/min to maintain MAP > 60-70 mmHg, , or equivalent vasoconstrictor agent) for at least one hour
  • Serum lactate level > 6 mmol/l
  • Time to ROSC > 25 minutes

Exclusion Criteria:

  • Evidence for patient's refusal to participate in clinical trials
  • Non commitment for ongoing medical therapy (imminent withdrawal of care)
  • Cardiac arrest caused by hemorrhagic shock
  • Contraindications to therapeutic heparinization
  • Shock of primary cardiac origin (LVEF <20%)
  • Platelet count <20 G/L
  • Deep immunosuppression state, as defined by neutrophils <1 G/L or CD4 <200 /mm3
  • Pregnancy
  • Acute sickle cell crisis
  • Refractory cardiac arrest with ECMO implantation
  • Need for renal replacement therapy at time of randomization
  • Concomitant enrolment in another study
  • Non availability of the research team at time of eligibility at time of randomization

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03523039

Layout table for location contacts
Contact: Antoine Schneider, MD, PhD +41795561902
Contact: Mauro Oddo, MD, PD +4121 314 39 23

Layout table for location information
Centre Hospitalier Universitaire Vaudois Recruiting
Lausanne, Vaud, Switzerland, 1011
Contact: Antoine Schneider, MD, PhD         
Sponsors and Collaborators
Centre Hospitalier Universitaire Vaudois
Layout table for investigator information
Principal Investigator: Antoine Schneider, MD, PhD Centre Hospitalier Universitaire Vaudois
Layout table for additonal information
Responsible Party: Antoine Schneider, Doctor, Centre Hospitalier Universitaire Vaudois Identifier: NCT03523039    
Other Study ID Numbers: ID 2018-00421
First Posted: May 14, 2018    Key Record Dates
Last Update Posted: January 27, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Antoine Schneider, Centre Hospitalier Universitaire Vaudois:
Cardiac Arrest
Cytokine Hemoadsorption
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Arrest
Heart Diseases
Cardiovascular Diseases